Chronic Rhinosinusitis with Nasal Polyps (incidence 1% in adult patients): injection site reactions, eosinophilia, insomnia, toothache, gastritis, arthralgia, and conjunctivitis
Studies show GLP-1 receptor agonists can help reduce body weight by 5-15% when combined with lifestyle modification, though menopause-specific outcomes require individualized assessment
Pfizer #Reports #Strong Phase 2b #Results for #Monthly #GLP-1 Candidate #Berobenatide, Advancing Broad Phase 3 Obesity Program Pfizer unveiled detailed Phase 2b data for berobenatide (PF-07976016/PF3944) at ADA 2026, highlighting the potential of what could become the first monthly GLP-1 receptor agonist peptide for obesity management
Lucena, R
Note: A great healthcare plan shouldnt have financial surprises
Compounding pharmacies are experts at stepping in when drug shortages occur